Here, we describe the first two cases of CML patients with BCR::ABL1 transcripts quantifiable on the IS achieving a sustained TFR after discontinuing asciminib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.